U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H14N4O3
Molecular Weight 226.2325
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARNOSINE

SMILES

NCCC(=O)N[C@@H](CC1=CN=CN1)C(O)=O

InChI

InChIKey=CQOVPNPJLQNMDC-ZETCQYMHSA-N
InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H14N4O3
Molecular Weight 226.2325
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Carnosine is a dipeptide composed of the amino acids beta-histidine and l-alanine. It is widely present in muscle and brain tissues. It possesses strong and specific antioxidant properties, protects against radiation damage, and promotes wound healing. The antioxidant mechanism of carnosine is attributed to its chelating effect against metal ions, superoxide dismutase (SOD)-like activity, ROS and free radicals scavenging ability. In addition, was shown, that carnosine significantly protects against TCA-induced liver carcinogenesis in rats, through its antioxidant, antinutritive, and anti-inflammatory effects, and induction of apoptosis. It also may be a therapeutic agent against Parkinson's disease. Experiments on animal have shown the sepsis healing therapeutic potential of carnosine.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Palliative
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
in rat liver carcinogenesis: carnosine (10mg/kg/day, i.p.) for 2 weeks. protective effect of carnosine on acute lung injury in sepsis rats: 25 mg/kg and 50 mg/kg, were administered for 30 consecutive days
Route of Administration: Other
In Vitro Use Guide
It was studied the anti-carcinogenic effect of L-carnosine in human carcinoma cells (SNU-423). The SNU-423 cancer cells were cultured at a density of 2 × 104 cells/well in Dulbecco modified Eagle medium. After 24 h of adherence, the cells were treated with L-carnosine (0.2 and 1 mg/mL) for 48 h. L-Carnosine significantly inhibited the growth of the SNU-423 cells (p < 0.05). The relative fluorescent unit was increased in a dose-dependent manner by L-carnosine, with values of 79.43, 186.87 and 400.89 for 0.6, 0.8 and 1 mg/mL of L-carnosine, respectively (p < 0.05).
Substance Class Chemical
Record UNII
8HO6PVN24W
Record Status Validated (UNII)
Record Version